HealthGlobal Inequality in Cancer Genetic Testing Highlighted by Lancet
A Lancet Oncology commission reveals significant global disparities in access to cancer genetic testing and treatments. Only 2% of biomarker-based cancer trials occur in low- and middle-income countries, while 81% are in high-income nations. The report warns that rapid growth in precision oncology has increased costs and complexity faster than population benefits. Global cancer drug spending reached $252 billion in 2024.
Hindu Health·3h ago




